HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.

Abstract
Interpretation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveillance studies is limited by poorly defined performance of antibody assays over time in individuals with different clinical presentations. We measured antibody responses in plasma samples from 128 individuals over 160 days using 14 assays. We found a consistent and strong effect of disease severity on antibody magnitude, driven by fever, cough, hospitalization, and oxygen requirement. Responses to spike protein versus nucleocapsid had consistently higher correlation with neutralization. Assays varied substantially in sensitivity during early convalescence and time to seroreversion. Variability was dramatic for individuals with mild infection, who had consistently lower antibody titers, with sensitivities at 6 months ranging from 33 to 98% for commercial assays. Thus, the ability to detect previous infection by SARS-CoV-2 is highly dependent on infection severity, timing, and the assay used. These findings have important implications for the design and interpretation of SARS-CoV-2 serosurveillance studies.
AuthorsMichael J Peluso, Saki Takahashi, Jill Hakim, J Daniel Kelly, Leonel Torres, Nikita S Iyer, Keirstinne Turcios, Owen Janson, Sadie E Munter, Cassandra Thanh, Joanna Donatelli, Christopher C Nixon, Rebecca Hoh, Viva Tai, Emily A Fehrman, Yanel Hernandez, Matthew A Spinelli, Monica Gandhi, Mary-Ann Palafox, Ana Vallari, Mary A Rodgers, John Prostko, John Hackett Jr, Lan Trinh, Terri Wrin, Christos J Petropoulos, Charles Y Chiu, Philip J Norris, Clara DiGermanio, Mars Stone, Michael P Busch, Susanna K Elledge, Xin X Zhou, James A Wells, Albert Shu, Theodore W Kurtz, John E Pak, Wesley Wu, Peter D Burbelo, Jeffrey I Cohen, Rachel L Rutishauser, Jeffrey N Martin, Steven G Deeks, Timothy J Henrich, Isabel Rodriguez-Barraquer, Bryan Greenhouse
JournalScience advances (Sci Adv) Vol. 7 Issue 31 (Jul 2021) ISSN: 2375-2548 [Electronic] United States
PMID34330709 (Publication Type: Journal Article)
CopyrightCopyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: